CG Oncology, Inc. Common stock

NASDAQ:CGON

Biotechnology

Healthcare
$80.00 +2.23%

+$1.35 today

Market cap
$7.15B
Beta
0.31
P/E (TTM)
-28.0
EPS (TTM)
-$2.21
52W Low $23.65High $75.50

Volume 1.79M

Average 1.08M

CGON Accounts Payables

Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.

CG Oncology, Inc. Common stockNASDAQ: CGON

Accounts Payables · Q3 FY2026 · quarter ended Sep 2026

Accounts payables turns negative

Q3 FY2026 accounts payables was -$2.96M, compared with $1.23M a year earlier. Trailing-twelve-month accounts payables was $579K. Over 3 fiscal years it compounded at +350.3% a year.

Context

  • Accounts payables amounted to 40.7% of revenue in FY2025, down 246.8 pp from a year earlier.
  • Accounts payables increased in 2 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly accounts payables holds near -$2.96M or moves back toward the trailing-twelve-month quarterly average of $144.75K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterSep 2026
-$2.96M-165.8% QoQ
Last fiscal yearDec 2025
-$1.64M-150.2% YoY
LTMSep 2026
$579K-86.5% YoY
Accounts Payables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-340.8%——
1 year-150.2%——
3-year CAGR+350.3%——
5-year CAGR——
10-year CAGR——

Accounts Payables history

USD · from the cash flow

Latest · FY2025
(1.64M) USD
Year-over-year change
-150.2%

Accounts Payables vs competitors

How CGON compares with its peers on the latest reported figures

  • CGON's LTM Sep 2026 accounts payables of $579K is the smallest of the 3 companies compared; the peer median is $5.77M.
  • Its year-over-year change of -86.5% is the lowest of 3, against a peer median of +94.4%.
  • Accounts payables amounts to 9.4% of revenue for CGON, versus a peer median of 3.6%.
CGON Competitors Peer median
Accounts Payables for CGON and competitors
Company Period LTM YoY 3-year CAGR% of revenue
IBRXImmunityBio, Inc.LTM Sep 2026$6.44M +246.9%—3.5%
URGNUroGen Pharma Ltd.LTM Mar 2026$5.1M -58.1%+0.6%3.6%
CGONCG Oncology, Inc. Common stockLTM Sep 2026$579K -86.5%+350.3%9.4%
Peer median (excluding CGON) $5.77M+94.4%+0.6%3.6%

Competitors are the stored peer set for CGON. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(12.84M)(35.44M)(48.61M)(88.04M)(161M)
Depreciation & Amortization10K15K17K32K1.45M
Deferred Income Tax00000
Stock-Based Compensation1.11M676K1.53M11.4M26.68M
Change in Working Capital(1.97M)4.44M3.44M2.91M2.28M
Accounts Receivables000(689K)(320K)
Inventory0000(444K)
Accounts Payables578K(18K)2.01M3.28M(1.64M)
Other Working Capital(2.55M)4.46M1.43M320K4.68M
Other Non-Cash Items30K509K(2.06M)(5.01M)(1.75M)
Operating Cash Flow(13.65M)(29.8M)(45.68M)(78.71M)(132.35M)
Capital Expenditures(97K)(14K)0(234K)(134K)
Acquisitions (Net)0000(21.97M)
Purchases of Investments0(55.34M)(517.61M)(1.05B)(1.07B)
Sales of Investments00396.42M745.41M844.14M
Other Investing Activities00000
Investing Cash Flow(97K)(55.35M)(121.2M)(300.76M)(245.82M)
Debt Repayment15.2M0(16.29M)(365K)0
Common Stock Issued245K166K2.08M629.47M153.59M
Common Stock Repurchased00000
Dividends Paid00000
Other Financing Activities00(3.42M)(825K)0
Financing Cash Flow15.45M119.69M87M628.28M153.59M
Effect of Forex Changes00000
Net Change in Cash1.7M34.54M(79.88M)248.8M(224.58M)
Free Cash Flow(13.75M)(29.82M)(45.68M)(78.95M)(132.48M)

CG Oncology, Inc. Common stock

NASDAQ:CGON

Intrinsic Alpha fair value

Locked

Current Price

$80.00

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.